Paul Jeng
Stock Analyst at Guggenheim
(2.86)
# 1,329
Out of 5,182 analysts
10
Total ratings
66.67%
Success rate
36.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Paul Jeng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Maintains: Buy | $50 → $54 | $29.48 | +83.18% | 3 | Apr 14, 2026 | |
| ADAG Adagene | Maintains: Buy | $9 → $10 | $3.56 | +180.90% | 2 | Apr 6, 2026 | |
| CNTX Context Therapeutics | Reiterates: Buy | $5 | $2.34 | +113.68% | 2 | Mar 24, 2026 | |
| IMTX Immatics | Maintains: Buy | $16 → $19 | $11.35 | +67.40% | 2 | Nov 18, 2025 | |
| IMCR Immunocore Holdings | Assumes: Neutral | n/a | $28.56 | - | 1 | Sep 18, 2025 |
IDEAYA Biosciences
Apr 14, 2026
Maintains: Buy
Price Target: $50 → $54
Current: $29.48
Upside: +83.18%
Adagene
Apr 6, 2026
Maintains: Buy
Price Target: $9 → $10
Current: $3.56
Upside: +180.90%
Context Therapeutics
Mar 24, 2026
Reiterates: Buy
Price Target: $5
Current: $2.34
Upside: +113.68%
Immatics
Nov 18, 2025
Maintains: Buy
Price Target: $16 → $19
Current: $11.35
Upside: +67.40%
Immunocore Holdings
Sep 18, 2025
Assumes: Neutral
Price Target: n/a
Current: $28.56
Upside: -